BIODESIX INC Stock Price, News & Analysis

Biodesix (NASDAQ: BDSX) reported strong Q2 2025 financial results with total revenue of $20.0 million, up 12% year-over-year. The company achieved an impressive 80% gross margin, a 150-basis point improvement from Q2 2024. Lung Diagnostic Testing revenue increased 8% to $17.9 million, while Development Services revenue grew 53% to $2.1 million.

Key operational highlights include expanding their sales team to 74 representatives (21% increase), achieving over 100% growth in primary care ordering of lung diagnostic tests, and reaching $12.5 million in development services contracts. Despite these improvements, the company reported a net loss of $11.5 million. Biodesix reaffirmed its full-year 2025 revenue guidance of $80-85 million and expects to achieve Adjusted EBITDA positivity in Q4 2025.

Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on August 12, 2025, at 4:30 PM ET in Boston, MA.

The presentation will be accessible via live webcast and available for replay in the Investors section of biodesix.com under "News & Events".

Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has scheduled its Q2 2025 financial results release for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET the same day to discuss results and provide business updates.

Management will conduct a Q&A session for analysts, and a webcast replay will be available on the investor website approximately two hours after the call concludes. Participants are encouraged to join 15 minutes before the start time.

Biodesix (NASDAQ: BDSX) has partnered with the Association of Pulmonary Advanced Practice Providers (APAPP) to launch the first CME-accredited educational programs focused on diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs. The collaboration aims to educate healthcare providers about innovative lung nodule risk assessment tools like the Nodify Lung blood-based tests and cancer treatment decision support testing such as IQLung blood-based tests. The initiative addresses the critical need for improved lung cancer detection, as lung cancer remains the deadliest cancer type, with 1 in 18 Americans expected to receive a diagnosis in their lifetime. The partnership focuses on empowering providers in both rural and metropolitan settings to better serve diverse patient populations despite resource limitations.

Biodesix (NASDAQ: BDSX) announced new data from the INSIGHT study on their VeriStrat Host Immune Classifier (HIC) test will be presented at the 2025 ASCO Annual Meeting. The study, involving over 5,000 NSCLC patients, demonstrates the test's ability to predict overall survival in non-small cell lung cancer patients receiving immunotherapy.

Key findings show that patients with VeriStrat Poor results had significantly improved survival when receiving combined immunotherapy and chemotherapy versus immunotherapy alone, with two-year survival rates more than tripling. Patients with VeriStrat Good results showed comparable survival with either treatment. Preliminary results suggest potential applications for other solid tumors, with additional data expected later in 2025.

Biodesix (NASDAQ: BDSX), a diagnostic solutions company, has announced its participation in two upcoming investor conferences. The company will attend the 22nd Annual Craig-Hallum Institutional Investor Conference for one-on-one meetings on May 28, 2025, in Minneapolis, MN. Additionally, Biodesix will present at the 45th Annual William Blair Growth Stock Conference on June 4, 2025, at 9:20 AM CT in Chicago, IL. The William Blair conference presentation will be available via webcast and can be accessed through the Investors section of Biodesix's website under \"News & Events\".

Biodesix (NASDAQ: BDSX) announced new data presentations for its Nodify Lung® Tests at two major conferences: ISPOR 2025 and ATS 2025. At ISPOR, a study of over 350,000 patients revealed concerning trends in lung nodule management: approximately two-thirds of patients receive no clinical work-up after nodule discovery, 60% of biopsies were performed on benign nodules, and 35% of malignant nodules only received follow-up CT scans before diagnosis.

At ATS 2025, an independent study from Wyckoff Heights Medical Center will present results from 103 patients who received Nodify Lung testing, demonstrating the test's role in lung cancer screening programs and its potential to guide management decisions through actionable results.

Biodesix (NASDAQ: BDSX) has been named a Colorado Top Workplaces 2025 Winner, marking its second consecutive year of workplace excellence recognition. The award, part of an 18-year-old program celebrating people-first organizations, was based on confidential employee feedback collected through Energage's third-party survey. Biodesix was among only 150 companies to receive this recognition.

The diagnostic solutions company's workplace culture was evaluated on various themes, including employee respect, support, growth opportunities, and execution empowerment. This achievement follows their 2024 Inc. Magazine Best Workplaces award, demonstrating consistent excellence in workplace culture. CEO Scott Hutton credited the team members for their role in creating a high-performing workplace culture while serving healthcare customers, patients, and industry partners.

Biodesix (NASDAQ: BDSX) reported Q1 2025 financial results with total revenue of $18.0 million, up 21% year-over-year. The company's diagnostic testing revenue increased 18% to $16.3 million, marking the 16th consecutive quarter of >15% growth. Development Services revenue grew 61% to $1.7 million. Gross margins improved to 79.4%. Net loss improved by 18% to $11.1 million, while Adjusted EBITDA loss improved 11% to $6.2 million. Following a successful commercial pilot, Biodesix reconfigured its sales team structure to target pulmonology and primary care physicians. Due to implementation delays, the company revised its 2025 revenue guidance to $80-85 million but maintains its expectation for Adjusted EBITDA positivity in Q4. Post-quarter, Biodesix secured $10 million from Tranche C of its term loan facility, bringing pro forma cash balance to $27.6 million.